{"id":132725,"date":"2026-07-21T14:03:10","date_gmt":"2026-07-21T14:03:10","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/132725\/"},"modified":"2026-07-21T14:03:10","modified_gmt":"2026-07-21T14:03:10","slug":"anthropic-novo-nordisk-eli-lilly-medicare-readout-newsletter","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/132725\/","title":{"rendered":"Anthropic, Novo Nordisk, Eli Lilly, Medicare: Readout Newsletter"},"content":{"rendered":"<p>\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"80\" height=\"80\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/07\/elaine-chen-avatar-round-80x80.png\" class=\"avatar-thumbnail\" alt=\"\" loading=\"lazy\"  \/>\t\t\t\t\t\t\t<\/p>\n<p class=\"author-title\">National Biotech Reporter<\/p>\n<p>\t\t\t\t\t\t\t<a class=\"social-item-icon twitter\" title=\"X\" href=\"https:\/\/x.com\/elaineywchen\" target=\"_blank\" rel=\"noopener nofollow\"><br \/>\n\t\t\t\t\t\t\t\t<a class=\"social-item-icon bluesky\" title=\"Bluesky\" href=\"https:\/\/bsky.app\/profile\/elaineywchen.bsky.social\" target=\"_blank\" rel=\"noopener nofollow\"><br \/>\n\t\t\t\t\t\t\t\t<a class=\"social-item-icon email\" title=\"Email\" href=\"http:\/\/www.statnews.com\/cdn-cgi\/l\/email-protection#f1949d90989f94df9299949fb1828590859f948682df929e9c\" target=\"_blank\" rel=\"noopener nofollow\"><br \/>\n\t\t\t\t\t\t\t\t<a class=\"social-item-icon linkedin\" title=\"Linkedin\" href=\"https:\/\/www.linkedin.com\/in\/elaineywchen\/\" target=\"_blank\" rel=\"noopener nofollow\"><\/p>\n<p class=\"author-bio\">Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes <a href=\"https:\/\/www.statnews.com\/signup\/readout\/\" rel=\"nofollow noopener\" target=\"_blank\">The Readout newsletter<\/a>, and co-hosts STAT\u2019s weekly biotech podcast, <a href=\"https:\/\/www.statnews.com\/category\/readout-loud\/\" rel=\"nofollow noopener\" target=\"_blank\">The Readout Loud<\/a>. You can reach Elaine on Signal at elaineywchen.70.<\/p>\n","protected":false},"excerpt":{"rendered":"National Biotech Reporter Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways&hellip;\n","protected":false},"author":2,"featured_media":132726,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[2759,4240,5794,272,5356],"class_list":["post-132725","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-biotechnology","tag-drug-development","tag-drug-prices","tag-novo-nordisk","tag-research"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116958344497352225","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/132725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=132725"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/132725\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/132726"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=132725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=132725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=132725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}